Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estim

President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes

Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with the

The recommendations of Wall Street analysts are often relied on by investors when deciding whether t

In July 2026, the European Medicines Agency (EMA) accepted the application to expand marketing autho

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United S

Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took foc

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pe

Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the pric

Merck & Co., Inc. NYSE: MRK reported second-quarter revenue of $16.6 billion, up 5% from a year earl

Total Revenue: $16.6 billion, an increase of 5% (4% excluding foreign exchange).KEYTRUDA Family Sale

Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, promp

Merck cuts FY2026 adjusted EPS outlook nearly in half to $2.66-$2.76, citing $2.43/share in charges

Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quart

Stock futures are building on the strong start to August, today buzzing on Strait of Hormuz buzz

Merck (MRK) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of

Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biote

Merck & Co (NYSE:MRK) lowers FY2026 Adj EPS guidance from $5.04-$5.16 to $2.66-$2.76 vs $2.76 an

Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue

Merck beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed

Merck & Co (NYSE:MRK) reported quarterly losses of $(0.13) per share which beat the analyst cons

The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Fi

Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Con

Merck & Co., Inc. NYSE: MRK outlined its HIV treatment and prevention strategy at an investor event

Argent Capital Management LLC increased its holdings in Merck and Co., Inc. (NYSE: MRK) by 5,236.8%

Merck and Wellcome-backed Hilleman will manufacture Bundibugyo Ebola vaccine doses for clinical tria

Barclays analyst Emily Field maintains Merck & Co (NYSE:MRK) with a Overweight and raises the

Scott warns China’s new drug rules could threaten U.S. medicine security, urging America to reduce r

Initial access plans as part of Merck’s broader strategy include establishing early generic licensin

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppressio

For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as &#34

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casda

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL c

At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C

Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemot

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the Phase 3

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises t

BMO Capital analyst Evan David Seigerman maintains Merck & Co (NYSE:MRK) with a Outperform an

Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the pric

Merck & Co. shares are in focus Monday after a wave of analyst activity capped by a new FDA appr

Scott urges Trump admin to increase tariffs on Chinese generic drug makers, citing forced labor &amp

Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24

US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials

FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Pha